The immunocytokine NHS-IL12 as a potential cancer therapeutic

被引：0
|
作者：
Fallon, Jonathan K. [1 ]
Tighe, Robert [2 ]
Lyon, Amanda J. [1 ]
Sabzevari, Helen [2 ]
Schlom, Jeffrey [1 ]
Greiner, John W. [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] EMD Serono, Billerica, MA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-2573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2573
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
    Waldhauer, Inja
    Gonzalez-Nicolini, Valeria
    Freimoser-Grundschober, Anne
    Nayak, Tapan K.
    Fahrni, Linda
    Hosse, Ralf J.
    Gerrits, Danny
    Geven, Edwin J. W.
    Sam, Johannes
    Lang, Sabine
    Bommer, Esther
    Steinhart, Virginie
    Husar, Elisabeth
    Colombetti, Sara
    Van Puijenbroek, Erwin
    Neubauer, Markus
    Cline, J. Mark
    Garg, Pradeep K.
    Dugan, Gregory
    Cavallo, Federica
    Acuna, Gonzalo
    Charo, Jehad
    Teichgraeber, Volker
    Evers, Stefan
    Boerman, Otto C.
    Bacac, Marina
    Moessner, Ekkehard
    Umana, Pablo
    Klein, Christian
    MABS, 2021, 13 (01)
  • [42] IL-17, an important prognostic factor and potential therapeutic target for breast cancer?
    Bian, Geng
    Zhao, Wen-Ying
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2014, 44 (02) : 604 - 605
  • [43] Targeting IL22: a potential therapeutic approach for Kras mutant lung cancer?
    Weinberg, Frank D.
    Ramnath, Nithya
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S243 - S247
  • [44] CDK12: cellular functions and therapeutic potential of versatile player in cancer
    Pilarova, Kveta
    Herudek, Jan
    Blazek, Dalibor
    NAR CANCER, 2020, 2 (01):
  • [45] Therapeutic potential of dual CDK12 and 13 inhibition in colorectal cancer
    Altunel, Erdem
    Zokaasadi, Mohammad
    Somarelli, Jason A.
    McCall, Shannon J.
    Gultawatvichai, Patan
    Whalen, Giles Francis
    Pitarresi, Jason
    Hsu, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] SNHG12: An LncRNA as a Potential Therapeutic Target and Biomarker for Human Cancer
    Tamang, Suraksha
    Acharya, Varnali
    Roy, Deepronil
    Sharma, Rinka
    Aryaa, Apeksha
    Sharma, Uttam
    Khandelwal, Akanksha
    Prakash, Hridayesh
    Vasquez, Karen M.
    Jain, Aklank
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [47] The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer
    Wagner, Karola
    Schulz, Petra
    Scholz, Arne
    Wiedenmann, Bertram
    Menrad, Andreas
    CLINICAL CANCER RESEARCH, 2008, 14 (15) : 4951 - 4960
  • [48] Therapeutic potential of targeting IL-17
    Sarah A Jones
    Caroline E Sutton
    Daniel Cua
    Kingston H G Mills
    Nature Immunology, 2012, 13 (11) : 1022 - 1025
  • [49] PHASE 1B STUDY OF AVELUMAB+M9241 (NHS-IL12) IN PATIENTS WITH ADVANCED SOLID TUMORS: INTERIM ANALYSIS RESULTS FROM A UROTHELIAL CARCINOMA (UC) DOSE-EXPANSION COHORT
    Deville, Jean-Laurent
    Ravaud, Alain
    Maruzzo, Marco
    Gourdin, Theodore
    Maio, Michele
    Dirix, Luc
    Wang, XiaoZhe
    Vugmeyster, Yulia
    Beier, Frank
    Seebeck, Jeorg
    Chennoufi, Sarah
    Gulley, James
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A163 - A163
  • [50] Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer
    Connor, JP
    Felder, M
    Hank, J
    Harter, J
    Gan, J
    Gillies, SD
    Sondel, P
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (03) : 211 - 219
12345